Physicians should be cautious when treating patients with lung cancer after progression on nivolumab because nivolumab-refractory lung cancer could have a significant response to salvage chemotherapy, according to a new study.
Physicians should be cautious when treating patients with lung cancer after progression on nivolumab because nivolumab-refractory lung cancer could have a significant response to salvage chemotherapy, according to a new study.
Although salvage chemotherapy after nivolumab therapy has demonstrated potential efficacy, there is minimal information on the clinical and immunologic features in lung cancer patients where the treatment is unsuccessful.
In a new study, published in Thoracic Cancer, the researchers hypothesized that chemotherapy improved the balance between immunostimulator and immunosuppressive cells to synergize with the immunostimulatory effects of the previous nivolumab treatment. In order to test this, the researchers conducted 2 case reports with 2 nivolumab refractory lung-cancer patients.
The first patient was a 66-year-old female, current smoker, who was diagnosed with stage IV undifferentiated non-small cell lung cancer (NSCLC) with bone metastasis. Her treatment was not successful and, following an additional 6 cycles of nivolumab, disease progression still occurred. However, when the nivolumab treatment regimen changed to the oral chemotherapy S-1 at a dose of 60 mg twice daily for 28 days, the tumor regressed and the patient remained progression-free for 5 months.
“Although the definition and exact mechanisms of pseudoprogression following nivolumab therapy remain undetermined, we considered this possibility in our cases. In Case 1, the tumor enlarged and respiratory symptom worsened after the 18-week observation period during nivolumab therapy,” the authors noted. “On review of previous clinical trials for NSCLC, symptomatic pseudoprogression was uncommon at nine weeks after the initiation of nivolumab.”
The second case report was a 75-year-old man who was a former smoker and diagnosed with stage IIIA lung adenocarcinoma with pulmonary metastases. The patient’s treatment, including chemotherapy were not originally successful and after 6 cycles of nivolumab, disease progression was evident. When the patient’s treatment changed to carboplatin/albumin-bound paclitaxel, his tumor rapidly regressed.
“In conclusion, physicians should be cautious when treating patients after progression on nivolumab because nivolumab-refractory lung cancer could show a remarkable response to salvage chemotherapy,” the study concluded.
The study calls for further research with a larger cohort to determine the extent of benefits of salvage chemotherapy and how the responders are selected.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More